RxDoctor Payments Data

Deniz Cayir

Medical · Denville, NJNPI 1225609894

Payments from drug & device makers

$1,555in general payments, 2019–2025

Across 34 payments — averaging $45.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$506
  • Novo Nordisk$254
  • Merck$243
  • Abiomed$162
  • Boston Scientific$149
  • Pfizer$55
  • plus $185 from 7 others

What the payments were for

  • Food & beverage$1,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,555 in reported general payments places this provider in the 70th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey

Medicare billing

Part B allowed, 2024
$48,045
Medicare patients
285
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$26,390
EntrestoSacubitril/Valsartan19$23,004
XareltoRivaroxaban24$22,680
VerquvoVericiguat11$9,989
Metoprolol Succinate132$1,221
Cilostazol66$1,153
Atorvastatin Calcium102$1,139
Losartan Potassium113$775
Amlodipine Besylate132$646
ClopidogrelClopidogrel Bisulfate41$478
Bupropion Hcl11$399
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide28$283
Rosuvastatin Calcium25$267
Carvedilol35$261
Albuterol Sulfate HfaAlbuterol Sulfate15$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$26,39024 claims
MerckVerquvo$243$9,98911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 573 medical providers in New Jersey.

Other medical in Denville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →